CLINICAL TRIAL SUMMARY

MDACC Study No:2011-0035 (clinicaltrials.gov NCT No: NCT01321554)
Title:A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Principal Investigator:Mouhammed A. Habra
Treatment Agent:E7080
Study Status:Open
Study Description:Unavailable

Hide details for General InformationGeneral Information

Disease Group:Thyroid
Phase of Study:Phase III
Treatment Agents:E7080
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Eisai
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Mouhammed A. Habra
Dept:Endocrine Neoplasia & Hormonal Disorders
For Clinical Trial Enrollment:713-792-2841
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults